What is the incentive for MNTA to settle with TEVA???????????
1. Lovenox - MNTA believes that TEVA and the competition do not have the technical skills and/or will infringe MNTA patents. TEVA has received a minor deficiency letter from FDA and has signaled that they will not talk about the program ....until its approved by the FDA - as Dew and others have stated - in their opinion teva generix lovenox is DEAD - WHERE IS THE INCENTIVE????????did you all forget that TEVA and MNTA have agreed to a protracted litigation schedule which may indicate that TEVA is in no hurry to get their generic lovenox approved? I am pretty sure that TEVA let MNTA look at their cards before mnta would agree to this bs trial date.
2. Copaxone - Novartis/MNTA have sued TEVA to invalidate their patents which have been obtained under questionable terms. MNTA has fully characterized Copaxone and all is left is FDA approval. I guessed June 2011, however if they are invoved in running the human equivalent trial - i would say be end of year MNTA gets the approval from FDA. If i were MNTA/Novartis, i would launch at risk and let them come after me in court.
TEVA has nothing on MNTA - just look at their stock price.